Abstract 1129P
Background
Osimertinib has been the standard of care of T790M mutation positive non–small-cell lung cancer (NSCLC) patients progressed from first-/second-generation EGFR-TKI for years. Here we report the real-world outcomes of second-line osimertinib for NSCLC patients in China.
Methods
Data of NSCLC patients who were treated with osimertinib based therapy in the second line setting were retrospectively collected from 10 hospitals in China between March 25, 2017 and December 31, 2021. The patient baseline characteristics, treatment patterns, and clinical outcomes, including objective response rate (ORR), disease control rate (DCR), and progression free survival (PFS) were analyzed.
Results
Datasets from a total of 566 eligible patients were included for analysis. The median age was 60 years, 323 (57.1%) were female, 480 (84.7%) were adenocarcinoma, 470 (83%) had stage IV disease, and 119 (21%) patients had documented brain metastases. Amongst all, 393 (69.4%) patients were treated with second-line osimertinib as monotherapy, including 282 patients harbored EGFR T790M positive mutation, of whom the ORR of was 57.4% (162/282), DCR was 95.7% (270/282), and the median PFS reached 14.5 months (19del subgroup: 15.4 months; L858R subgroup: 13.8 months). Besides, the other 111 patients had received second-line osimertinib monotherapy without documented EGFR T790M mutation, providing an ORR of 23.4%, DCR of 52.3%, and a median PFS of 6.7 months. In overall, the safety profile of osimertinib was manageable and consistent with the previous reports, no new safety signals were identified.
Conclusions
This real-world analysis further confirmed the therapeutic effectiveness and safety of osimertinib as second-line treatment in NSCLC patients with EGFR T790M mutations with consistent benefit across different subgroups and highlighted the needs for routine T790M testing for patients progressed after first-/second-generation EGFR-TKIs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.